中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.017 seconds)

    METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION
    2.
    发明申请
    METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION 审中-公开
    治疗方法和药物组合物

    公开(公告)号：US20130158085A1

    公开(公告)日：2013-06-20

    申请号：US13686411

    申请日：2012-11-27

    Applicant: Novartis AG

    Inventor： Gary Michael Ksander ,  Randy Lee Webb

    IPC: A61K31/41 ,  A61K31/197 ,  A61K31/216

    CPC classification number: A61K31/41 ,  A61K31/192 ,  A61K31/197 ,  A61K31/216 ,  A61K31/222 ,  A61K45/06 ,  A61K2300/00

    Abstract: The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, diabetic retinopathy, the management of other vascular disorders, cognitive dysfunction, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.

    Abstract translation: 本发明涉及药物组合物，其包含以下组合：（i）AT 1拮抗剂缬沙坦或其药学上可接受的盐; 和（ii）NEP抑制剂或其药学上可接受的盐和任选的药学上可接受的载体，以及用于治疗或预防选自高血压，心力衰竭（如急性和慢性）的病症或疾病的方法 ）充血性心力衰竭，左心室功能障碍和肥大性心肌病，糖尿病性心肌病，室上性和室性心律失常，房颤，心房扑动，有害血管重塑，心肌梗死及其后遗症，动脉粥样硬化，心绞痛（不稳定或不稳定），肾功能不全 糖尿病和非糖尿病），心力衰竭，心绞痛，糖尿病，继发性醛固酮增多症，原发性和继发性肺动脉高压，肾衰竭病症，糖尿病性视网膜病变，其他血管疾病的管理，认知功能障碍，包括施用治疗有效量的药物 组合物到哺乳动物 需要它。

    Methods of treatment and pharmaceutical composition
    5.
    发明授权
    Methods of treatment and pharmaceutical composition 有权
    治疗方法和药物组成

    公开(公告)号：US08796331B2

    公开(公告)日：2014-08-05

    申请号：US13687659

    申请日：2012-11-28

    Applicant: Novartis AG

    Inventor： Gary Michael Ksander ,  Randy Lee Webb

    IPC: A61K31/235 ,  A61K31/41 ,  A61K31/195

    CPC classification number: A61K31/41 ,  A61K31/192 ,  A61K31/197 ,  A61K31/216 ,  A61K31/222 ,  A61K45/06 ,  A61K2300/00

    Abstract: The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, diabetic retinopathy, the management of other vascular disorders, cognitive dysfunction, comprising administering a therapeutically effective amount of tire pharmaceutical composition to mammal in need thereof.

    Abstract translation: 本发明涉及药物组合物，其包含以下组合：（i）AT 1拮抗剂缬沙坦或其药学上可接受的盐; 和（ii）NEP抑制剂或其药学上可接受的盐和任选的药学上可接受的载体，以及用于治疗或预防选自高血压，心力衰竭（如急性和慢性）的病症或疾病的方法 ）充血性心力衰竭，左心室功能障碍和肥大性心肌病，糖尿病性心肌病，室上性和室性心律失常，心房颤动，心房扑动，有害血管重塑，心肌梗死及其后遗症，动脉粥样硬化，心绞痛（不稳定或不稳定），肾功能不全 糖尿病和非糖尿病），心力衰竭，心绞痛，糖尿病，继发性醛固酮增多症，原发性和继发性肺动脉高压，肾衰竭病症，糖尿病性视网膜病变，其他血管疾病的管理，认知功能障碍，包括施用治疗有效量的轮胎药物 组合成哺乳动物 需要它。

    METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION
    6.
    发明申请
    METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION 有权

    公开(公告)号：US20130158086A1

    公开(公告)日：2013-06-20

    申请号：US13687659

    申请日：2012-11-28

    Applicant: Novartis AG

    Inventor： Gary Michael Ksander ,  Randy Lee Webb

    IPC: A61K31/41 ,  A61K31/197 ,  A61K31/222

    CPC classification number: A61K31/41 ,  A61K31/192 ,  A61K31/197 ,  A61K31/216 ,  A61K31/222 ,  A61K45/06 ,  A61K2300/00

    Abstract: The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, diabetic retinopathy, the management of other vascular disorders, cognitive dysfunction, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.

Patent Agency Ranking